Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
about
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic reviewPhase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.Current classification, treatment options, and new perspectives in the management of adipocytic sarcomasPazopanib in the treatment of soft tissue sarcomaPredictive value of clinical judgment of tumour progression in phase II trials.Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trialA retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatmentsRetroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcomaPrimary intrathoracic malignant neurogenic tumor: report of three cases and comparison with benign neurogenic tumors resected at our institution.Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report.A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas.Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcomaProgressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.Primary central nervous system angiosarcoma: two case reportsTrabectedin in the neoadjuvant treatment of high-grade pleomorphic sarcoma: report of a rare case and literature review.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial resultsPhase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study.Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.Histologic variability and diverse oncologic outcomes of prostate sarcomas.Integrative genomic and transcriptomic analysis of leiomyosarcoma.Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).Role of dacarbazine in the treatment of recurrent mullerian adenosarcoma with sarcomatous overgrowth: Our experience.Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.
P2860
Q26822530-164714C9-637D-4558-B21D-1CCDE85A400BQ27852177-247F5351-19FB-40A9-8201-CAB4D6ED7D59Q28076210-895C299D-18D3-4B28-91DD-8F2684E96304Q28269229-0A03707F-BADC-4468-85C3-A26CFC37D527Q34540982-282E9B55-072E-45CF-A05E-83AEF0B8D9D6Q34736667-92785A1F-6B1A-4353-964E-3C16DE5179FCQ35206566-26F88C3C-36D4-49B7-AB37-D9ED942E067BQ35427293-6BE99EB8-5DFE-4D97-B28D-896EE0230367Q35611855-B999AC88-F721-4567-8082-21AE017234FCQ35776264-55E274ED-D216-41F0-860F-166E20D5BE30Q36547967-FC0F75FE-FA7C-4891-84A6-33525E73DFF3Q36564034-FB02E7C2-2743-4826-AEFA-D860D5F3BABAQ36591503-D538D231-EA64-4662-ADAC-EEA66083B69BQ37043932-5965F1FD-86C6-4FDC-B5ED-43A609E1884EQ37190323-EA3F2B74-AA72-4BC5-B339-A7B568985F36Q37222064-69976197-5746-43D3-BEB3-34BC336E2A59Q37449674-466E3D64-D4C7-4449-8627-1E38E5B37C7EQ38036372-40C8FA87-EDA7-4CE6-B30D-E839B3B99FE6Q38080848-461510A8-F925-4F84-8847-813C3423E02AQ38161734-B9E4A7E2-9698-404B-AD69-973B0FF723FCQ38763415-516E4423-728F-485A-9550-77CDA9DB5BCEQ39324450-9CA06890-61AD-4900-BF9A-D053D6C80F76Q39683594-74A35A60-9231-46B4-9A83-29FB16395208Q42614042-177937AB-1663-40A1-B0BE-172A7767F18FQ47739736-65553F43-22A6-47B5-B398-DF9AED5042EEQ51066747-7F8302C7-5FD4-445F-B7E3-71B3C1B7E88DQ53109459-D5AB89CF-2B7F-451A-9A0C-1128D589B7EDQ55192373-4A7612C5-A3FE-44A0-BA36-0FD6B9E3CDFB
P2860
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Testing new regimens in patien ...... ations from the last 10 years.
@en
Testing new regimens in patien ...... ations from the last 10 years.
@nl
type
label
Testing new regimens in patien ...... ations from the last 10 years.
@en
Testing new regimens in patien ...... ations from the last 10 years.
@nl
prefLabel
Testing new regimens in patien ...... ations from the last 10 years.
@en
Testing new regimens in patien ...... ations from the last 10 years.
@nl
P2093
P2860
P356
P1433
P1476
Testing new regimens in patien ...... cations from the last 10 years
@en
P2093
M Van Glabbeke
P Hohenberger
S Marreaud
P2860
P304
P356
10.1093/ANNONC/MDQ608
P577
2010-12-23T00:00:00Z